Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer

Erlotinib is active in patients with lung cancer; especially those who demonstrate a mutation in exons 18-21 in the epidermal growth factor receptor (EGFR) gene. Patients with lung cancer and brain metastases have poor prognosis as systemic chemotherapy is ineffective in treating the central nervous...

Descripción completa

Detalles Bibliográficos
Autores principales: Jabbari, Siavash, Pins, Michael, Kruczek, Kimberly, Nabhan, Chadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507060/
https://www.ncbi.nlm.nih.gov/pubmed/23210009
http://dx.doi.org/10.4103/2231-0770.90916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507060/
https://www.ncbi.nlm.nih.gov/pubmed/23210009
http://dx.doi.org/10.4103/2231-0770.90916

Ejemplares similares